Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes-Reference-Cited by-同舟云学术

Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes

Published:2021-10-27 Issue:10 Volume:4 Page:e2130762
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Zhuo Min¹²³,Hawley Chelsea E.¹⁴,Paik Julie M.¹²⁵,Bessette Lily G.¹,Wexler Deborah J.⁶,Kim Dae H.¹⁷⁸,Tong Angela Y.¹,Kim Seoyoung C.¹⁹,Patorno Elisabetta¹

Affiliation:

1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

2. Division of Renal Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

3. Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

4. New England Geriatric Research, Education and Clinical Center, VA Bedford Healthcare System, Bedford, Massachusetts

5. New England Geriatric Research, Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts

6. Diabetes Center, Massachusetts General Hospital, Harvard Medical School, Boston

7. Marcus Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, Massachusetts

8. Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts

9. Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2785536/zhuo_2021_oi_210883_1634737287.27798.pdf

Reference56 articles.

1. Mortality implications of prediabetes and diabetes in older adults.;Tang;Diabetes Care,2020

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.;Zinman;N Engl J Med,2015

3. Canagliflozin and cardiovascular and renal events in type 2 diabetes.;Neal;N Engl J Med,2017

4. Dapagliflozin in patients with chronic kidney disease.;Heerspink;N Engl J Med,2020

5. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.;Perkovic;N Engl J Med,2019

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality;Diabetology & Metabolic Syndrome;2024-09-06

2. Unleashing frailty from laboratory into real world: A critical step toward frailty‐guided clinical care of older adults;Journal of the American Geriatrics Society;2024-08-21

3. Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data;Biomedicines;2024-07-07

4. Bone Loss in Diabetes Mellitus: Diaporosis;International Journal of Molecular Sciences;2024-07-02

5. Terpenoids as potential phytoconstituent in the treatment of diabetes: From preclinical to clinical advancement;Phytomedicine;2024-07